Citrine Global CEO Issues Letter to Shareholders
Retrieved on:
Wednesday, April 13, 2022
Dry, Use, Research, Science, GLOBE, Risk, Technology, OTCQB, Port, Dizziness, Saliva, Acquisition, Quality of life, Side, Treatment, Seed, Mineral, Plant, Annual report, Private Securities Litigation Reform Act, Entrepreneurship, Canadian International Council, Company, Solution, TM, Xerostomia, IP, Nausea, Nature, Fatigue, Vitamin, Somnolence, Marketing, GMP, Ministry, Cosmetics, Method, United States patent law, Communication, Drink, SEC, Vomiting, University, S, Dental public health, Sleep, Taste, Start-up Nation, Relaxation, Oral, Hart Side, Patent, Letter, Headache, Industrialisation, Online gambling, Management, Fine chemical, Medicinal plants, Renewable energy, Dentistry, Drug, Interior design, Pharmaceutical industry, Nasdaq, Oh My Girl, Health, Cannabis, Cannabinoid
Tel Aviv, April 13, 2022 (GLOBE NEWSWIRE) -- Citrine Global Corp. (OTCQB: CTGL), a plant-based wellness and pharma solutions company, today issued a Letter to Shareholders from its CEO and Chairman, Ora Elharar-Soffer.
Key Points:
- Tel Aviv, April 13, 2022 (GLOBE NEWSWIRE) -- Citrine Global Corp. (OTCQB: CTGL), a plant-based wellness and pharma solutions company, today issued a Letter to Shareholders from its CEO and Chairman, Ora Elharar-Soffer.
- We are glad to provide an overview of the main milestones achieved by the Company during the last two years since the group of Citrine Global principal shareholders acquired the company and furnished the necessary funding for implementing our new strategic direction.
- Citrine Global's headquarters and senior management are based in Israel, where the company operates via its 100%-owned-subsidiary CTGL Citrine Global Israel Ltd. and 60%-owned Cannovation Center Israel Ltd.
- The Company is supported by a professional, experienced group of primary shareholders that include Citrine S A L Investment & Technologies.